Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG’s New HTG Transcriptome Panel Launched with Commercial Availability in the U.S. and Europe
HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the  HTG EdgeSeq technology Intended to serve as one of the technological cornerstones for the  recently announced HTG Therapeutics Business Unit A third white paper highlighting the HTG Transcriptome Panel’s
Toggle Summary HTG Molecular Diagnostics to Announce Second Quarter 2021 Financial Results and Host Conference Call on Thursday, August 12
TUCSON, Ariz. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , July 23, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that, on July 13th and July 22nd, 2021 the Compensation Committee of the HTG Board of Directors granted
Toggle Summary HTG Forms New Drug Discovery Business Unit
New unit to focus on development of drug candidates through use of HTG Transcriptome Panel TUCSON, Ariz. , July 20, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the creation of
Toggle Summary HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
TUCSON, Ariz. , June 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Additional proxy soliciting materials - definitive

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities